AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
AYTU BioPharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T21Q11
1.90▼ 0.08 (-4.04%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.98
Day's Range
1.90 – 2.00
52-Week Range
1.80 – 3.07
Volume
26.2K
Avg Volume
39.7K
Share Statistics
Shares Outstanding
Employees
83
Exchange
XNAS
Listed
2008-02-15
Share count as of September 15, 2026

AYTU BioPharma, Inc. Common Stock (AYTU) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about AYTU BioPharma, Inc. Common Stock (AYTU)
What is AYTU BioPharma, Inc. Common Stock's Market Cap?
AYTU BioPharma, Inc. Common Stock's Market Cap is $20.6M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Enterprise Value?
AYTU BioPharma, Inc. Common Stock's Enterprise Value is $5.3M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Price / Sales?
AYTU BioPharma, Inc. Common Stock's Price / Sales is 0.4×, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EV / Revenue?
AYTU BioPharma, Inc. Common Stock's EV / Revenue is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EV / EBITDA?
AYTU BioPharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Revenue (TTM)?
AYTU BioPharma, Inc. Common Stock's Revenue (TTM) is $57.6M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Net Income (TTM)?
AYTU BioPharma, Inc. Common Stock's Net Income (TTM) is -$14.3M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EBITDA?
AYTU BioPharma, Inc. Common Stock's EBITDA is -$5.7M, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's Diluted EPS (TTM)?
AYTU BioPharma, Inc. Common Stock's Diluted EPS (TTM) is -1.31, based on as-reported figures from SEC (XBRL) filings.
What is AYTU BioPharma, Inc. Common Stock's EBITDA Margin?
AYTU BioPharma, Inc. Common Stock's EBITDA Margin is -9.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AYTUAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenue
YoY growth+6.4%-32.7%-6.5%-16.2%
Cost of goods sold
Gross profit
% of revenue64.6%61.2%63.5%66.1%
Operating expenses:
Selling and marketing
General and administrative
Research and development
Amortization of intangible assets
Restructuring costs
Impairment expense————
Total operating expenses
% of revenue69.5%94.0%76.5%77.0%
Loss from operations
% of revenue-4.8%-32.7%-13.0%-10.8%
Other income (expense), net
Interest expense
Derivative warrant liabilities loss
Loss from continuing operations before income tax expense
Income tax expense
Net loss from continuing operations
Net loss
% of revenue-0.1%-45.3%-69.8%14.1%
Basic and diluted - net loss (in dollars per share)